SS-31, also known as elamipretide, is now FDA-approved as FORZINITY for one narrow indication, muscle strength in Barth syndrome, under accelerated approval resting on a surrogate endpoint. Every other use it was tested for, including mitochondrial myopathy, heart failure, heart attack recovery and dry macular degeneration, failed its primary endpoint. A 2026 FDA warning letter named the same molecule as an unapproved product when sold by research-peptide vendors, months after its approval for the one indication it does have.
Ask about SS-31
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Szeto-Schiller (SS) mitochondria-targeted tetrapeptide |
| Primary research interest | Mitochondrial dysfunction; approved specifically for muscle strength in Barth syndrome |
| Highest available evidence | FDA-approved prescribing information (accelerated approval, surrogate endpoint) |
| Human research available | Yes: extensive: Barth syndrome (TAZPOWER), heart failure (PROGRESS-HF), STEMI (EMBRACE), primary mitochondrial myopathy (MMPOWER-2/3), and several ophthalmic trials; most non-Barth trials were negative on their primary endpoint |
| Development status | Approved for one narrow indication; broader mitochondrial-disease program largely unsuccessful |
| Regulatory status | FDA accelerated approval as FORZINITY (elamipretide hydrochloride injection), 19 September 2025, for Barth syndrome only; FDA warning letters issued 24 August 2026 against vendors marketing unapproved “SS-31 (Elamipretide)” |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | SS-31 (research/discovery name); Elamipretide (INN/USAN) |
| Alternative names | MTP-131, Bendavia (early development codes); brand name FORZINITY (hydrochloride salt, approved product); SS-31 is the 31st compound in the Szeto-Schiller peptide series |
| Peptide sequence | D-Arg-Dmt-Lys-Phe-NH2 (D-arginine-2,6-dimethyltyrosine-lysine-phenylalanine amide) |
| Amino-acid length | 4 residues (synthetic aromatic-cationic tetrapeptide) |
| Molecular formula | C32H49N9O5 (free base) |
| Molecular weight | Approximately 639.8 g/mol (free base) |
| CAS Registry Number | 736992-21-5 (free base); 72244098-12-0 (hydrochloride salt, the marketed FORZINITY form) |
| PubChem CID | 11764719 |
| Chemical modifications | D-amino acid and 2,6-dimethyltyrosine substitutions giving an amphipathic, cationic structure that concentrates in the mitochondrial inner membrane and binds cardiolipin; C-terminal amide |
| Peptide class | Szeto-Schiller (SS) mitochondria-targeted peptide |
| Primary biological target | Cardiolipin, an anionic phospholipid of the inner mitochondrial membrane |
| Developer or originator | Stealth BioTherapeutics Inc. |
| Development status | Approved (Barth syndrome only); other indications discontinued or unsuccessful in late-stage trials |
What it is
SS-31 is the laboratory name for a synthetic aromatic-cationic tetrapeptide, D-arginine-2,6-dimethyltyrosine-lysine-phenylalanine amide, developed by Hazel Szeto and Peter Schiller and numbered the 31st compound in their peptide series. The molecule later carried the development codes MTP-131 and Bendavia, and its International Nonproprietary Name is elamipretide. As of 19 September 2025, elamipretide hydrochloride is also the active ingredient of an approved US drug, sold under the brand name FORZINITY. In the primary literature, SS-31, MTP-131, Bendavia and elamipretide all refer to the same chemical entity across every stage of its development; what changed over time was the salt form used in the marketed product and, most recently, its regulatory status.
That last point makes this entry different from most others on this site. Elamipretide is not simply an unapproved research peptide, and it is not simply an approved drug either. It is both, depending on who is selling it and for what.
Mechanism
SS-31 is described in the primary literature as an amphipathic, polybasic peptide that partitions into lipid bilayer interfacial regions and is proposed to concentrate at the inner mitochondrial membrane because that membrane is unusually rich in the anionic phospholipid cardiolipin. Biophysical and computational work in model bilayers, isolated mitochondria and a yeast system found that the peptide did not destabilize lamellar membranes even at high binding concentrations, but did alter lipid packing and membrane surface electrostatics, a mechanism the study’s authors proposed as the likely basis of its reported mitochondrial-protective effects, rather than a classical receptor interaction.
The clinical literature has repeated a downstream hypothesis built on that biophysical finding: that stabilizing cardiolipin preserves the organization of electron transport chain complexes, improves oxidative phosphorylation, and reduces reactive oxygen species leakage. That causal chain has not been measured directly in the same human trial in the sources reviewed for this entry. The trials that exist measured functional outcomes, such as walk distance and muscle strength, not electron transport chain efficiency in patients. A 2025 review on mitochondrial approaches to kidney injury identified a protein called phospholipid scramblase 3 as an emerging mediator of the peptide’s protective effects in preclinical models, while cautioning that mitochondrial peptide therapies including this one face translational hurdles including limited bioavailability, difficulty establishing effective dosing, and incomplete mechanistic understanding. That caveat, from researchers studying the compound’s own proposed mechanism, is worth holding onto when reading any of the sections below.
What is approved, and at what dose
A record of what the FDA had approved as of 18 September 2026, not an instruction.
FORZINITY (elamipretide hydrochloride injection) was granted accelerated approval on 19 September 2025 under New Drug Application 215244. The label states the indication as improving muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms. Barth syndrome is a rare, X-linked genetic disorder caused by mutations in the TAZ gene that impair remodeling of cardiolipin, the same lipid the peptide is proposed to bind.
The label’s own limitations-of-use language is the single sentence that governs how this entry should be read: the indication was approved under accelerated approval, based on an improvement in knee extensor muscle strength, described as an intermediate clinical endpoint, and continued approval may be contingent on verification of clinical benefit in a confirmatory trial. In plain terms, the drug was approved because it moved a muscle-strength surrogate in a small trial population, not because a completed trial demonstrated improved survival, cardiac function, or another outcome patients would directly feel. That confirmatory trial, registered as a Phase 3b/4 study in genetically confirmed Barth syndrome patients, was reported as recruiting as of this writing, with a primary completion date years away.
The approved dose is 40 mg injected subcutaneously once daily, reduced to 20 mg once daily in patients with severe renal impairment not on dialysis, rotated between the abdomen and outer thigh. There is no boxed warning. The label’s contraindication is limited to serious hypersensitivity to elamipretide or its excipients. Because the multi-dose vial is preserved with benzyl alcohol, the label states the product should not be used in neonates, a restriction that, combined with the 30-kilogram weight floor, excludes an approved use in the youngest and often most severely affected Barth syndrome patients. In the small trial that underlies the label, injection site reactions were reported in essentially all treated patients, and this pattern of frequent local reactions, not systemic toxicity, has been the dominant safety finding across the entire elamipretide program.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Barth syndrome (FDA-approved indication) | Subcutaneous injection | 40 mg (20 mg in severe renal impairment not on dialysis) | Once daily | Ongoing/chronic, per label | FDA-approved prescribing information (FORZINITY, NDA 215244) |
| Heart failure with reduced ejection fraction, primary mitochondrial myopathy, STEMI, and other tested indications | Subcutaneous or intravenous, depending on trial | Doses up to 40 mg/day tested across the late-stage program (TAZPOWER, MMPOWER-2/3, ReCLAIM-2, PROGRESS-HF) | Once daily (SC programs) or as infusion (early IV studies) | Weeks to months, per trial | Published human clinical trials; primary endpoints not met in these indications |
| General mitochondrial-support framing | Subcutaneous | A few milligrams per day, below the 40 mg/day approved and studied dose | Once daily | Not established | Community / vendor reported |
How the approval actually happened
The regulatory history behind that one approved sentence is unusually long and worth telling as a sequence rather than compressing into “approved.” Stealth BioTherapeutics submitted its first New Drug Application for elamipretide in Barth syndrome on 24 August 2021. The FDA issued a Refusal to File on 20 October 2021, a pre-review administrative rejection meaning the agency judged the application incomplete before review even began. Advocacy records show the application was subsequently reassigned between three different FDA review divisions over roughly two and a half years, reflecting difficulty classifying a therapy for a rare, multi-system disease within the agency’s organizational structure.
A resubmitted application was accepted for filing on 3 April 2024 and granted Priority Review the following month. On 10 October 2024, FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 10 to 6 in favor of approval for the Barth syndrome indication. Despite that favorable vote, FDA issued a Complete Response Letter on 29 May 2025, declining to approve the application as submitted. Stealth announced a third resubmission on 18 August 2025, and FDA granted accelerated approval one month later, on 19 September 2025. The application was not killed by the Complete Response Letter; it was redirected, from a standard-approval submission toward one resting on the muscle-strength surrogate, and the redirected version succeeded.
The approval carries post-marketing requirements beyond the confirmatory efficacy trial, including a mouse carcinogenicity study and a two-year rat carcinogenicity study, meaning the drug reached the market before its long-term carcinogenic potential in standard rodent testing had been characterized.
Potential benefits and research applications
Muscle strength in Barth syndrome, the one demonstrated benefit
What is being investigated: whether elamipretide improves muscle strength and function in Barth syndrome, a rare genetic disorder that impairs cardiolipin remodeling in mitochondria. How the effect might occur: by binding and stabilizing cardiolipin at the inner mitochondrial membrane, proposed to preserve electron transport chain organization. Evidence: the TAZPOWER trial and its open-label extension reported a cumulative 96.1-meter improvement in six-minute walk distance by week 168, alongside improved echocardiographic measures. Strength: has been shown well enough to support FDA accelerated approval. Limitation: the approval rests on an intermediate surrogate endpoint, knee extensor muscle strength, in a trial of only 12 patients, and continued approval is contingent on a confirmatory trial that had not reported at the time of this entry.
General mitochondrial support, an idea the broader trial record does not support
What is being investigated: whether stabilizing cardiolipin and mitochondrial membrane structure could benefit conditions beyond Barth syndrome, including primary mitochondrial myopathy, heart failure, heart attack recovery and dry macular degeneration. How the effect might occur: the same proposed cardiolipin-stabilization mechanism, applied more broadly. Evidence: none of strength; every one of these programs failed its stated primary endpoint in controlled human trials. Strength: has not been established for any use outside Barth syndrome. Limitation: this is the clearest example on this site of an approved-drug mechanism story being generalized well past what its own trial record supports, and it is exactly the framing used by vendors selling the same molecule as an unapproved “SS-31” research peptide.
Barth syndrome: the trial the approval rests on
The pivotal trial, known as TAZPOWER, was a small, randomized, double-blind, placebo-controlled crossover study at a single site, enrolling 12 male patients age 12 and older with genetically confirmed Barth syndrome, followed by a long open-label extension. In the open-label extension, reported at week 168, ten patients entered and eight completed. Six-minute walk distance improved at every assessed time point, reaching a cumulative improvement of 96.1 meters by week 168. Echocardiographic measures of left ventricular volume also improved over the same period, and a disease-specific lipid biomarker improved in a pattern the study’s authors reported as correlating with the clinical changes.
Because Barth syndrome is ultra-rare, a large placebo-controlled trial was not considered practical, so the sponsor built a retrospective natural-history comparison cohort of 19 untreated patients and compared it, via propensity scoring, to the eight patients who remained on treatment through the open-label extension. That comparison favored elamipretide on walk distance and handheld dynamometry-measured muscle strength. This is the strongest efficacy claim in the Barth syndrome program, and it should be read as exactly what it is: an uncontrolled, retrospective, propensity-matched comparison in a disease population of a few dozen genetically confirmed patients worldwide, not a randomized result.
Every other indication tested: a program of negative trials
Outside Barth syndrome, elamipretide has been tested across primary mitochondrial myopathy, dry age-related macular degeneration, heart failure, and acute heart attack, and every one of those programs failed on its stated primary endpoint.
In primary mitochondrial myopathy, the Phase 2 crossover trial MMPOWER-2 missed its primary six-minute-walk endpoint, reporting a 19.8-meter difference against placebo that did not reach significance, though several patient-reported fatigue measures improved. The Phase 3 trial that followed, MMPOWER-3, enrolled 218 patients and was terminated after not demonstrating a significant benefit in its overall, genotypically diverse population, according to the investigators’ own published account. A post hoc subgroup analysis suggested a possible effect in patients with mitochondrial DNA replisome-related disorders, but that subgroup finding came from a negative trial, and the dedicated follow-up study designed to test it, NuPOWER, completed without a located published result. There is no approved indication for elamipretide in primary mitochondrial myopathy of any genotype.
In dry age-related macular degeneration, the Phase 2 trial ReCLAIM-2 did not meet either of its co-primary endpoints, low-luminance visual acuity and geographic atrophy area. A secondary, exploratory endpoint measuring preservation of photoreceptor structure did show a statistically significant effect, and that surrogate has since been made the primary endpoint of an ongoing Phase 3 trial, ReNEW, which has not yet reported results. As of this writing there is no FDA approval and no completed Phase 3 result in this indication.
In heart failure, the Phase 2 trial PROGRESS-HF found no significant difference from placebo on its primary cardiac MRI endpoint in patients with reduced ejection fraction, with the trial’s own authors concluding the drug did not improve that measure. A larger acute decompensated heart failure trial enrolling more than 300 patients completed without a located published efficacy result. In first-time anterior heart attack undergoing emergency angioplasty, the Phase 2 trial EMBRACE STEMI found no difference in infarct size between elamipretide and placebo, and the authors reported no improvement on any prespecified imaging, electrocardiographic, or clinical outcome. There is no cardiovascular indication anywhere in this compound’s regulatory history.
Put together, the Barth syndrome approval is a narrow exception inside a much larger record of trials that did not confirm a clinical benefit. The evidence tier assigned to this entry, E1, reflects the genuine approved-label evidence that exists for Barth syndrome specifically. It does not extend to any other proposed use, all of which sit at a lower tier: failed or unproven Phase 2 and Phase 3 results, hypothesis-generating post hoc subgroups, or preclinical mechanism alone.
Safety
Injection site reactions are, by a wide margin, the most consistently reported adverse finding across the entire program, present from early Phase 1 studies through the approved label. In the trial underlying approval, erythema was reported in all treated patients against a quarter of placebo patients, with pain, pruritus and induration also more common on treatment. The Phase 2 dose-ranging trial in mitochondrial myopathy reported injection site reactions in 80 percent of treated participants, and the AMD trial ReCLAIM-2 reported adverse events in 86 percent of treated patients versus 71 percent on placebo, again dominated by local reactions.
No serious systemic safety signal has emerged across the trials reviewed, and multiple studies describe the drug as well tolerated at the systemic level, with the important caveat that most trials enrolled small numbers of patients and none has run long enough to characterize rare serious events. The longest published human exposure data are the Barth syndrome open-label extension at 168 weeks in a handful of patients and the AMD trial at 48 weeks. As noted above, the FDA’s own post-marketing requirements include carcinogenicity studies that had not completed at the time of approval.
What circulates
This compound is not on this site’s circulating-figures exclusion list, so what follows records the general pattern found in circulating research-peptide material, without naming any vendor, without a date, and without treating the figure as guidance.
Material sold as “SS-31” circulates as lyophilized powder in small vials, typically marketed under research-use-only framing. The route described in circulating material, subcutaneous, and the once-daily frequency both broadly match the studied and approved route and frequency, which is unusual for a compound on this site. Where circulating material states a dose, it commonly describes a daily amount of a few milligrams, which sits below the 40 mg once-daily dose used in essentially every late-stage human trial of this compound and in the approved FORZINITY label, including the Barth syndrome pivotal trial, both mitochondrial myopathy Phase 2 and 3 trials, the AMD Phase 2 trial, and one arm of the heart failure trial. Across every one of those late-stage trials, the studied subcutaneous dose is the same 40 mg once daily, which gives this comparison an unusually clean anchor: the approved and studied dose is consistent, and circulating material describing a lower daily figure sits below all of it, not above it, which is the less common pattern on this site.
Circulating material of this kind typically does not cite the FDA label’s approved dose, the accelerated-approval and surrogate-endpoint limitation, the benzyl-alcohol and neonatal warning, or the narrow Barth-syndrome-only indication, and it typically continues to describe the compound as a purely investigational research peptide, predating or ignoring the September 2025 approval. Where such material claims a general anti-aging, mitochondrial-support, or performance benefit, that claim conflicts directly with the single narrow indication on the approved label and with the negative results recorded above for heart failure, heart attack, and general-population mitochondrial myopathy.
Approved and warned against, at the same time
FDA issued a warning letter dated 24 August 2026 to a research-peptide vendor, naming “SS-31 (Elamipretide)” among several other compounds marketed on the vendor’s site, roughly eleven months after FORZINITY’s approval. The letter’s cited legal basis was that the vendor’s product is a new drug, lacking an approved application for the use for which it was being marketed, introduced into interstate commerce unlawfully. A second warning letter from the same period named the same compound alongside several others, indicating this was part of a coordinated sweep across multiple peptide products rather than an action aimed at elamipretide specifically.
The two facts sit side by side and both are true. Elamipretide hydrochloride is an FDA-approved prescription drug, sold as FORZINITY, for one narrow rare-disease indication, in patients weighing at least 30 kilograms, at a specific dose, under an approval that remains contingent on a confirmatory trial still years from reporting. The same molecule, sold by research-peptide vendors as “SS-31” for unsupervised use and for indications that were never demonstrated to work, or that failed outright in controlled trials, is not a lawful version of that drug and was the subject of a federal warning letter after the approval, not before it. An approved application for one indication does not make an unapproved, differently labeled, differently dosed version of the same molecule lawful for any other use, and nothing about the Barth syndrome approval changes what the primary mitochondrial myopathy, heart failure, heart attack, and dry AMD trials actually found.
Frequently asked questions
What is SS-31?
SS-31 is a synthetic tetrapeptide also known as elamipretide, approved by the FDA as FORZINITY for improving muscle strength in Barth syndrome. The same molecule sold by research-peptide vendors as “SS-31” is unapproved for any other use.
How does it work?
It is proposed to bind cardiolipin, a lipid concentrated at the inner mitochondrial membrane, stabilizing membrane structure and, hypothetically, electron transport chain function. That downstream chain has not been directly measured in a human trial.
What dosage has been studied?
The approved and studied dose across every late-stage trial, in Barth syndrome, mitochondrial myopathy, dry AMD and heart failure, is the same: 40 mg subcutaneously once daily, reduced to 20 mg in severe renal impairment.
What dosage commonly circulates online?
Circulating research-market material commonly describes a low single-digit-milligram daily dose, below the 40 mg used in every studied trial and the approved label. The route and frequency broadly match what was studied, but the amount does not.
Has it been studied in humans?
Extensively. It has completed trials in Barth syndrome, primary mitochondrial myopathy, dry age-related macular degeneration, heart failure and acute heart attack. Only the Barth syndrome trial supported approval; every other program failed its primary endpoint.
Is it the same thing as the approved drug FORZINITY?
Chemically, yes, the molecule is identical. Legally, no: FORZINITY is an approved prescription drug for one narrow indication at a specific dose, while “SS-31” sold by research-peptide vendors is an unapproved product, the subject of a 2026 FDA warning letter.
What side effects have been reported?
Injection site reactions, including erythema, pain and itching, are the dominant finding, reported in nearly all treated patients across trials. No serious systemic safety signal has emerged, though FDA required post-marketing rodent carcinogenicity studies that had not completed at approval.
Is it approved?
Yes, but only for one use: improving muscle strength in Barth syndrome patients weighing at least 30 kg, under accelerated approval. It has no approval for mitochondrial myopathy, heart failure, heart attack recovery, macular degeneration, or general anti-aging or performance use.
What remains unknown?
Whether the Barth syndrome benefit holds up in the required confirmatory trial; whether any genotype of mitochondrial myopathy responds; whether the AMD structural signal will translate into a vision benefit; and the drug’s long-term carcinogenic risk, since it reached market before rodent carcinogenicity testing completed.
Bottom line
SS-31/elamipretide is a genuine regulatory success story wedged inside an otherwise disappointing trial record. It earned FDA accelerated approval as FORZINITY for one narrow, rare-disease indication, resting on a surrogate muscle-strength endpoint in a trial of just 12 patients, with confirmatory data still years away. Every other indication tested, spanning mitochondrial myopathy, heart failure, heart attack recovery and dry macular degeneration, failed its primary endpoint. The molecule sold as an unapproved “SS-31” research peptide is chemically the same compound but legally a different product, one that drew a federal warning letter months after the approved version reached the market.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| FORZINITY, approved (Barth syndrome) | Subcutaneous | 40 mg once daily (20 mg in severe renal impairment) | Once daily | Ongoing, per label |
| TAZPOWER (Barth syndrome, pivotal trial) | Subcutaneous | 40 mg | Once daily | Crossover periods, then extension to 168 weeks |
| MMPOWER-2 and MMPOWER-3 (mitochondrial myopathy) | Subcutaneous | 40 mg | Once daily | 4 to 24 weeks |
| ReCLAIM-2 (dry AMD) | Subcutaneous | 40 mg | Once daily | 48 weeks |
| Commonly circulating research-market figure | Subcutaneous | Low single-digit milligrams per day | Once daily | Not standardised; below every approved and studied dose above |
Material sold as "SS-31" typically appears as lyophilized powder in small vials under research-use-only framing. The subcutaneous route and once-daily frequency described in this material broadly match the approved and studied route and frequency. Where a dose is stated, it commonly falls in the low single-milligram range per day, below the 40 mg once-daily dose used in the approved FORZINITY label and in every late-stage human trial of this compound. Such material typically predates or ignores the September 2025 approval, does not cite the approved label's indication or its accelerated-approval limitation, and often frames the compound as beneficial for uses, such as general anti-aging or performance support, that were never demonstrated and in several cases failed outright in controlled trials.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- FORZINITY (elamipretide hydrochloride) injection prescribing information, US Food and Drug Administration, NDA 215244, approved 19 September 2025. Source for the indication, the accelerated-approval and confirmatory-trial language, the 40 mg/20 mg dosing, contraindications, and the benzyl alcohol/neonatal warning. Human, regulatory. NDA 215244
- Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018. Human, n=36. Source for the mechanism description and the early IV dose-ranging signal. PMID 29500292
- Mitchell W, et al. Structural analysis of the SS-31 peptide and its cardiolipin-dependent effects on membrane electrostatics. J Biol Chem. 2020. Biophysical/computational, not whole-animal. Source for the cardiolipin-binding, membrane-electrostatics mechanism. PMID 32273339
- Patel S, Pabla N, Bajwa A. Mitochondrial-targeted therapies in acute kidney injury. Semin Nephrol. 2025. Preclinical/mechanistic review. Source for the PLSCR3 pathway and the authors' own caveat about incomplete mechanistic understanding. PMID 41027799
- Thompson WR, et al. Long-term open-label extension study of elamipretide in Barth syndrome (TAZPOWER). Genet Med. 2024. Human, n=8 completers at week 168. Source for the 96.1-meter six-minute-walk improvement, echocardiographic changes, and the MLCL/cardiolipin biomarker finding. PMID 38602181
- Hornby B, et al. Natural history comparison of elamipretide-treated Barth syndrome patients versus untreated controls. Orphanet J Rare Dis. 2022. Human, retrospective, propensity-matched, n=8 treated vs 19 untreated. Source for the walk-distance and muscle-strength comparison and its uncontrolled, retrospective design. PMID 36056411
- Karaa A, et al. Randomized crossover trial of elamipretide in primary mitochondrial myopathy (MMPOWER-2). J Cachexia Sarcopenia Muscle. 2020. Human, n=30. Six-minute-walk primary endpoint missed significance; several patient-reported fatigue measures improved. Source for the MMPOWER-2 result and the 80 percent injection-site-reaction rate. PMID 32096613
- Karaa A, et al. Post hoc genotype analysis of the MMPOWER-3 Phase 3 trial of elamipretide. Orphanet J Rare Dis. 2024. Human, n=218 enrolled overall. States the trial did not demonstrate a significant benefit in the overall population; source for the genotype subgroup finding and the terminated trial status. PMID 39574155
- Ehlers JP, et al. Phase 2 randomized trial of elamipretide in dry age-related macular degeneration (ReCLAIM-2). Ophthalmol Sci. 2024. Human, n=176. Co-primary endpoints missed; ellipsoid-zone secondary endpoint positive. Source for the AMD trial result and adverse event rate. PMID 39605874
- Butler J, et al. Elamipretide in heart failure with reduced ejection fraction (PROGRESS-HF). J Card Fail. 2020. Human, n=71. Primary cardiac MRI endpoint not met at either dose. Source for the heart failure trial result. PMID 32068002
- Gibson CM, et al. EMBRACE STEMI trial of intravenous MTP-131 (elamipretide/Bendavia) in anterior STEMI. Eur Heart J. 2015. Human, n=300. Primary infarct-size endpoint negative. Source for the STEMI trial result. PMID 26586786
- US Food and Drug Administration warning letter, 24 August 2026, naming "SS-31 (Elamipretide)" as an unapproved new drug when marketed by a research-peptide vendor, roughly eleven months after FORZINITY's approval for Barth syndrome. Regulatory. Warning letter 734884
Compare SS-31 with related compounds
Research area: Longevity and mitochondrial.